Sorafenib Pharmascience 200 mg, filmomhulde tabletten Países Bajos - neerlandés - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

sorafenib pharmascience 200 mg, filmomhulde tabletten

pharmascience international ltd lampousas 1 1095 nicosia (cyprus) - sorafenibtosylaat 274 mg/stuk samenstelling overeenkomend met ; sorafenib 200 mg/stuk - filmomhulde tablet - cellulose, microkristallijn (e 460) ; croscarmellose natrium (e 468) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; ijzeroxide rood (e 172) ; magnesiumstearaat (e 470b) ; natriumlaurilsulfaat (e 487) ; polyethyleenglycol (e 1521) ; titaandioxide (e 171)

Spikevax (previously COVID-19 Vaccine Moderna) Unión Europea - neerlandés - EMA (European Medicines Agency)

spikevax (previously covid-19 vaccine moderna)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccins - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

Ultifend ND IBD Unión Europea - neerlandés - EMA (European Medicines Agency)

ultifend nd ibd

ceva-phylaxia veterinary biologicals co. ltd - turkey herpes virus, strain rhvt/nd/ibd, expressing the fusion protein of newcastle disease virus and the vp2 protein of infectious bursal disease virus, live recombinant - immunologicals voor aves - embryonated chicken eggs; chicken - for the active immunisation of one-day-old chicks or 18-day-old chicken embryonated eggs to reduce mortality, clinical signs and lesions caused by newcastle disease virus (ndv) and to reduce virus shedding; to reduce mortality, clinical signs and bursa lesions caused by very virulent infectious bursal disease virus (ibdv); to reduce mortality, clinical signs and lesions caused by classical marek’s disease virus (mdv).

CircoMax Myco Unión Europea - neerlandés - EMA (European Medicines Agency)

circomax myco

zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - immunologicals voor suidae - varkens (voor de mesterij) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection.  onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination.  duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination.  in addition, vaccination has been shown to reduce body weight gain losses under field conditions.

Arexvy Unión Europea - neerlandés - EMA (European Medicines Agency)

arexvy

glaxosmithkline biologicals s.a.  - respiratory syncytial virus recombinant glycoprotein f stabilised in the pre-fusion conformation (rsvpref3) produced in chinese hamster ovary (cho) cells by recombinant dna technology - respiratoire syncytiële virusinfecties - vaccins - arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (lrtd) caused by respiratory syncytial virus in adults 60 years of age and older. het gebruik van dit vaccin moet gebeuren in overeenstemming met officiële aanbevelingen.

SevoFlo Unión Europea - neerlandés - EMA (European Medicines Agency)

sevoflo

zoetis belgium sa - sevofluraan - anesthetica, algemene - dogs; cats - voor de inductie en het behoud van anesthesie bij honden en katten.

Sevohale (previously known as Sevocalm) Unión Europea - neerlandés - EMA (European Medicines Agency)

sevohale (previously known as sevocalm)

chanelle pharmaceuticals manufacturing limited - sevofluraan - anesthetica, algemene - dogs; cats - voor de inductie en het onderhoud van anesthesie.

Dzuveo Unión Europea - neerlandés - EMA (European Medicines Agency)

dzuveo

laboratoire aguettant - sufentanil citraat - pijn - anesthetica - dzuveo is indicated for the management of acute moderate to severe pain in adult patients.

Xanthium - 200 200 mg harde caps. verl. afgifte Bélgica - neerlandés - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

xanthium - 200 200 mg harde caps. verl. afgifte

laboratoires s.m.b. sa-nv - theofyllinemonohydraat - eq. theofylline 200 mg - capsule met verlengde afgifte, hard - 200 mg - theofylline 200 mg - theophylline

Xanthium - 400 400 mg harde caps. verl. afgifte Bélgica - neerlandés - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

xanthium - 400 400 mg harde caps. verl. afgifte

laboratoires s.m.b. sa-nv - theofyllinemonohydraat - eq. theofylline 400 mg - capsule met verlengde afgifte, hard - 400 mg - theofylline 400 mg - theophylline